Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Amlodipine 10 mg Compared to Amlodipine 10 mg in Patients

NCT00841672 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00841672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00841672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Amlodipine 10 mg Compared to Amlodipine 10 mg in Patients
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2009
Completion date
September 30, 2009
Enrollment
485 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe hypertension